Stockwinners Market Radar for May 13, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:03 EDT Cathie Wood's ARK Investment buys 314K shares of Shopify today

19:50 EDT Tian Ruixiang Holdings Ltd trading halted, news pending

19:37 EDT Kodiak Sciences announces treatment of first patients in Phase3 Tarcocimab study - The company states: "Kodiak Sciences announced that the first patients with diabetic retinopathy have been treated in the randomized double masked Phase 3 GLOW2 study of tarcocimab tedromer. GLOW2 is the second Phase 3 study of tarcocimab in diabetic retinopathy in which all patients on investigational therapy will receive tarcocimab on extended dosing intervals, including 6-month dosing for all patients. The GLOW2 study design mirrors the successful GLOW1 study in which tarcocimab-treated patients, over the 48-week study duration, saw 29-fold increased response rate in greater than or equal to 2-step improvement in DRSS (treatment) and 89% decreased risk of developing sight-threatening complications. Consistent with Kodiak's operational track record of running six pivotal studies in parallel for the tarcocimab program, GLOW2 is on an accelerating trajectory of site activations, new patient screenings and randomizations with the goal to complete enrollment before the end of this year."

19:34 EDT Grocery Outlet director buys $2.1M in common stock - In a regulatory filing, Grocery Outlet disclosed that its director Erik Ragatz bought 100K shares of common stock on May 10th in a total transaction size of $2.1M.

18:13 EDT Learn CW Investment extends period to consummate business combination - Learn CW Investment announced that it has further extended the period of time the Company will have to consummate its initial business combination by an additional one month from May 13 to June 13 through the timely deposit of an aggregate of $150,000 into the Company's trust account. This Extension is the eighth of up to twelve one-month extensions permitted under the Company's governing documents, as amended pursuant to the Extraordinary General Meeting of the Company shareholders that took place on October 11, 2023.

18:05 EDT Pembina Pipeline receives TSX approval for NCIB renewal - Pembina Pipeline announced that the Toronto Stock Exchange, or TSX, has approved the renewal of Pembina's normal course issuer bid, or NCIB, to purchase up to five percent of its issued and outstanding common shares. Under the NCIB, purchases of common shares may be made through the facilities of the TSX, the New York Stock Exchange and/or alternative Canadian trading systems, commencing on May 16 and expiring on the earlier of May 15, 2025 and the date on which Pembina has acquired the maximum number of common shares allowable under the NCIB or the date on which Pembina otherwise decides not to make any further repurchases under the NCIB. As of May 8, 2024, Pembina had 579,531,577 common shares issued and outstanding and is therefore permitted to repurchase up to 28,976,578 common shares, being five percent of its issued and outstanding common shares, pursuant to the NCIB. Common shares purchased under the NCIB will be cancelled.

17:11 EDT B. Riley Financial delays filing 10-Q - The company stated: "B. Riley Financia is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the period ended March 31, 2024 by May 10, 2024, the required filing date, with the delay due in large part to the dedication of time and resources expended by the Company to complete its Annual Report on Form 10-K for the year ended December 31, 2023 which was filed on April 24, 2024. The Company is working diligently to file the Quarterly Report as promptly as practical and expects to file the Quarterly Report on May 15, 2024."

17:02 EDT Horizon Bancorp CFO Mark Secor to switch to CAO role, John Stewart to succeed - Horizon Bancorp announced that John Stewart has been named Horizon's next executive VP and CFO. Stewart will assume the responsibilities of CFO on May 20. Stewart succeeds Mark Secor, the bank's CFO for the past 16 years. Secor will remain with the organization taking on a new role of chief administration officer, or CAO, responsible for investor relations, legal, benefits administration and corporate facilities. Additionally, Secor will assist in the transition of the CFO role to Stewart. Both Stewart and Secor will report to Thomas Prame, CEO and president of Horizon Bank.

16:58 EDT Terran Orbital awarded subcontract by Lockheed for SDA's T2 Tracking Layer - Terran Orbital Corporation (LLAP) announced being selected by Lockheed Martin (LMT) to produce 18 satellite buses for their recent Space Development Agency Tranche 2 Tracking Layer contract. Lockheed Martin will provide the SDA with 16 wide field-of-view missile warning/missile tracking space vehicles with infrared sensors and two vehicles with missile defense infrared sensors that can generate fire control-quality tracks to provide preliminary missile defense mission capabilities. Each Lockheed Martin-built T2 Tracking Layer satellite will incorporate a Terran Orbital bus. "We're proud to once again be selected as the trusted space vehicle provider for Lockheed Martin, especially for the SDA's critical tracking mission," said Marc Bell, Terran Orbital's Co-Founder, Chairman, and Chief Executive Officer. "This continued partnership signifies the confidence Lockheed Martin places in Terran Orbital's capabilities. We are excited to leverage our expertise and deliver these advanced space vehicles to support the SDA's mission objectives."

16:43 EDT Stereotaxis to acquire Access Point Technologies in all-stock transaction - Stereotaxis announced that it has entered into a definitive share purchase agreement under which Stereotaxis will acquire Access Point Technologies, or APT, a privately-held Minnesota-based developer of electrophysiology catheters. The transaction consideration includes an upfront payment and additional contingent payments based upon the achievement of key regulatory and commercial milestones. All consideration is payable in Stereotaxis common stock. Stereotaxis currently estimates that APT will contribute approximately $5M in annual revenue during the first year post-acquisition. The acquisition is subject to customary closing conditions and is expected to close in the third quarter.

16:36 EDT Lottery.com engages financial advisor to help oversee and structure acquisitions - Lottery.com announces a significant step to accelerate its global expansion efforts. Lottery.com has engaged Cohen & Company Capital Markets , a division of J.V.B. Financial Group, as its financial advisor to help oversee and structure its acquisition strategy. The company's "buy and build" strategy is backed by the United Capital Investments Limited $150M loan facility with support from strategic investors, such as Prosperity InvestmentManagement. Under the new agreement, effective May 6 CCM will assist Lottery.com in navigating potential acquisitions and other business combinations aimed at enhancing the Company's product offerings and market reach. This partnership is designed to support the Company's "buy and build" strategy, targeting a pipeline of potential acquisitions over the next 12 months to bolster both domestic and international operations, as well as boosting technological and market capabilities.

16:29 EDT Theravance Biopharma sees FY24 R&D expenses $30M-$36M - Sees FY24 SG&A expenses of $45M-$55M in each case excluding share-based compensation. Sees FY24 share-based compensation expenses $18M-$22M. Expects Non-GAAP net loss in the first half of 2024 and to approach non-GAAP breakeven in the second half of 2024; limited cash burn expected in 2024.

16:17 EDT M/I Homes announces $250M share repurchase program - M/I Homes announced that its Board of Directors approved a new share repurchase authorization, pursuant to which the company may purchase up to $250M of its common shares. The $250M authorization replaces the company's prior authorization, which had $103M of remaining availability as of April 30.

16:16 EDT TechnipFMC awarded iEPCI contract by Woodside Energy - TechnipFMC has been awarded a significant integrated Engineering, Procurement, Construction, and Installation contract by Woodside Energy in Australia. TechnipFMC will design, manufacture, and install the subsea production system, flexible pipe, and umbilicals for the Xena Infill well to support ongoing production from the Pluto LNG Project. The award follows an integrated front end engineering design study. The project will use the Company's Subsea 2.0 production system. Xena Phase 3 will be tied back to existing subsea infrastructure previously supplied by TechnipFMC. For TechnipFMC, a "significant" contract is between $75M and $250M. This award will be included in inbound orders in the second quarter of 2024.

16:13 EDT Donaldson, PolyPeptide to partner in peptide purification - The company states: "Donaldson Company and PolyPeptide Group AG announced their collaboration on the development of a production scale solvent recovery system for use in peptide purification. Peptides are used as the active pharmaceutical ingredient in therapeutic areas, which continue to broaden and include metabolic disorders, oncology, infectious diseases, orphan diseases, cardiovascular, neurology or gastro-enterology applications. The collaboration between Donaldson and PolyPeptide marks a milestone in the pharmaceutical industry's pursuit of environmentally friendly manufacturing practices. By leveraging Donaldson's experience in filtration and separation technologies and PolyPeptide's expertise in peptide synthesis, the partnership aims to introduce a pioneering solution for reclaiming and purifying acetonitrile used in peptide purification. The technology is intended to be utilized for the benefit of the entire peptide manufacturing industry."

16:10 EDT GSE Systems names Damian DeLongchamp as COO - GSE Solutions announced the appointment of Damian DeLongchamp as COO. DeLongchamp has been with GSE for more than 7 years and most recently was the Vice President of GSE Programs and Performance group. He brings over 20 years of utility experience both domestically and abroad. His experience encompasses various roles in nuclear, fossil and green energy across a wide spectrum of managerial, operational, technical and engineering responsibilities.

16:05 EDT Senseonics, Mercy to partner on diabetes health management - Senseonics, in partnership with global commercial partner Ascensia Diabetes Care and St. Louis-based Mercy, a health care system and accountable care organization, announced a first-of-its-kind relationship in a diabetes population management program. The collaboration marks the first time Senseonics' Eversense CGM technology will be used across a health system and the first implementation of Senseonics' new Eversense Remote Patient Monitoring (RPM) solution to drive significant advancement in diabetes management for patients.

15:37 EDT Roku lands exclusive rights to MLB's Sunday Leadoff live games - Roku has secured the exclusive multi-year rights for Major League Baseball Sunday Leadoff live games. Starting May 19, Roku will offer Sunday MLB games for free on The Roku Channel, plus an all-new MLB Zone to help baseball fans discover live and upcoming games, nightly recaps, highlights, a fully programmed MLB FAST channel, and more across the Roku platform. On most Sundays throughout the season, Roku will be the home for the first games of the day, with an exclusivity window during airtime as well.

14:06 EDT Ubisoft confirms 'Assassin's Creed Red' official name 'Assassin's Creed Shadows' - Ubisoft said that its previously announced game "Assassin's Creed Codename Red" will be officially named "Assassin's Creed Shadows." The company will release a world premiere trailer for the game on May 15. Reference Link

12:35 EDT Plutonian Acquisition Corp trading resumes

12:00 EDT Beyond jumps 22% to $20.53 in midday trading

12:00 EDT NL Industries falls -12.9% - NL Industries is down -12.9%, or -$1.02 to $6.86.

12:00 EDT Beyond rises 20.3% - Beyond is up 20.3%, or $3.42 to $20.28.

12:00 EDT GameStop rises 61.3% - GameStop is up 61.3%, or $10.70 to $28.16.

11:38 EDT GeoPark enters asset purchase agreement with Phoenix Global - GeoPark Limited has signed an Asset Purchase Agreement with Phoenix Global Resources, a subsidiary of Mercuria Energy Trading, for the acquisition of non-operated working interest in four adjacent unconventional blocks in the Neuquen Basin in Argentina as follows: a 45% WI in each of the Mata Mora Norte producing block and Mata Mora Sur exploration block, located in Neuquen Province, and a 50% WI in each of the Confluencia Norte and Confluencia Sur exploration blocks, located in Rio Negro Province. GeoPark will pay $190 million for a total of 122,315 gross acres; In addition to the upfront consideration, GeoPark will fund 100% of exploratory commitments up to $113 million gross, to be funded over two years, an acquisition of midstream capacity according to the WI of $11 million, and a $10 million bonus contingent on results in the Confluencia exploration campaign The transaction is expected to close before the end of 3Q2024, pending customary regulatory approvals.

11:06 EDT Kimmeridge urges SilverBow shareholders to vote for its nominees - Kimmeridge, the largest shareholder of SilverBow Resources, holding 12.9% of outstanding shares, issued a letter to shareholders, which read in part, "Unfortunately, rather than engage constructively, the SilverBow Board of Directors has continued its long-standing pattern of prioritizing self-preservation over shareholder returns. In recent weeks, the incumbent Board has repeatedly misled shareholders about Kimmeridge's actions and intent. False Claim 1: SilverBow asserts that Kimmeridge nominated directors to the Board solely to force a combination with Kimmeridge Texas Gas. The Facts: Kimmeridge privately informed the Company on January 31, 2024 that it was planning to nominate directors to the Board and, on February 16, 2024, submitted its formal nomination notice to the Company.1 Following the submission of Kimmeridge's nomination notice, the Board met with Kimmeridge on February 21, 2024, and Kimmeridge privately outlined eight potential strategic transactions the Company could pursue to drive value, including the KTG Combination. During this meeting, the Board requested that Kimmeridge submit a proposal regarding the KTG Combination in writing. On February 26, 2024, SilverBow CEO Sean Woolverton called Kimmeridge founder Ben Dell to request a formal proposal for the KTG Combination. At this time, Mr. Woolverton and the Board were well aware that Kimmeridge had submitted nominees for election at SilverBow's 2024 Annual Meeting of Shareholders (the "Annual Meeting"). On March 13, 2024, following the Board's request, Kimmeridge delivered a financed, premium proposal, which mirrored the terms previewed with the Board on February 21, 2024. Make no mistake - the Board invited an offer from Kimmeridge with no intent of engagement or negotiation on the KTG Combination, knowing that it was facing a proxy contest, and then misstated this timeline to proxy advisors and shareholders, to misrepresent Kimmeridge's intent. False Claim 2: SilverBow stated that in January 2024 Kimmeridge threatened to take control of the Board through a proxy battle and did not engage in settlement discussions. The Facts: Contrary to what SilverBow claims, in emails sent on February 9, 2024 and February 13, 2024, Kimmeridge outlined a settlement to avoid a proxy contest; SilverBow ignored these overtures. Specifically, Kimmeridge requested that SilverBow appoint one new independent director and immediately de-stagger the Board or appoint two directors, one new and one replacement, and undertake a phased de-staggering of the Board. Additionally, Kimmeridge asked the Company to consider removing the poison pill and offered to commit itself to a standstill as a show of good faith. Kimmeridge never implied in its communications that the proxy contest would be used to take control of the Company. False Claim 3: SilverBow stated that Kimmeridge threatened to take control of the Company through a tender offer on March 31, 2023. The Facts: This is patently false: Kimmeridge never made such a statement or even raised the prospect of acquiring the Company through a tender offer - on March 31, 2023 or otherwise. Moreover, executing a tender offer without the Company's consent would not even have been possible considering there was and continues to be a poison pill in place. Kimmeridge has only made proposals to SilverBow at the Board's request. False Claim 4: The Board adopted a short duration poison pill to prevent Kimmeridge from acquiring the Company without paying any control premium. The Facts: In 2022, Kimmeridge thought it was negotiating a zero-premium merger between SilverBow and KTG. Prior to any meaningful engagement, the Board adopted what Kimmeridge understands to be the industry's only poison pill. Kimmeridge has not acquired any shares in over 670 days, even though its ownership sits well below the poison pill's 15% trigger. SilverBow's poison pill has never been about protecting shareholders' interests from a no-premium hostile takeover. It is about protecting management and the Board. SilverBow will never submit the poison pill to a shareholder vote because the Board knows shareholders won't support it. The Board unilaterally extended its long-term poison pill and has now conveniently scheduled the poison pill to expire the day after the Annual Meeting, but it will most likely be unilaterally extended - once again - by the Board."

10:36 EDT Philips Respironics announces recall of over 90,900 Trilogy EVO ventilators - The FDA announces the recall of 90,905 Philips Respironics Trilogy EVO, Trilogy EV300, Trilogy Evo O2, and Trilogy Evo Universal continuous ventilators due to a software-related possible power malfunction. The FDA has identified this as a Class I recall, the most serious type of recall, and says use of these devices without the software update may cause serious injuries or death, but notes that this recall is a correction, not a product removal. Philips Respironics has notified customers to update to the latest software version of its Trilogy Evo continuous ventilator devices, as these ventilators can issue a "Battery Depleted" or "Loss of Power" alarm while sufficient power is still available, resulting in a sudden loss of ventilation while the device alarms. Philips says all Trilogy Evo ventilators are susceptible to this problem, except those ventilators with the software version 1.05.06.00 installed. As of May 13, there are no reports of death or serious injury related to this issue, Philips said. Reference Link

10:17 EDT Rent the Runway trading halted, volatility trading pause

10:05 EDT GameStop more than doubles after 'Roaring Kitty' returns - Shares of GameStop are soaring after Keith Gill, known online as "Roaring Kitty," the persona which inspired the short squeeze of 2021, posted online for the first time in three years. Shares of GameStop are up 110%, or $19.24, to $36.70 in morning trading. The stock has been halted multiple timed for volatility.

10:01 EDT NL Industries falls -9.0% - NL Industries is down -9.0%, or -71c to $7.17.

10:00 EDT Seritage Growth Properties falls -35.4% - Seritage Growth Properties is down -35.4%, or -$3.30 to $6.02.

10:00 EDT AMC Entertainment rises 24.4% - AMC Entertainment is up 24.4%, or 71c to $3.62.

09:54 EDT Walgreens jumps 6% to $18.29 after Bloomberg report of Boots sale process

09:48 EDT AMC Entertainment rises 15.8% - AMC Entertainment is up 15.8%, or 46c to $3.37.

09:47 EDT NL Industries falls -7.7% - NL Industries is down -7.7%, or -61c to $7.27.

09:47 EDT Chimera falls -8.0% - Chimera is down -8.0%, or -37c to $4.24.

09:45 EDT Cytokinetics announces additional results of SEQUOIA-HCM trial - Cytokinetics announced that additional results from SEQUOIA-HCM the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy, elaborating on dosing and safety data as well as the effect of aficamten on exercise performance were presented at Heart Failure 2024, an International Congress of the European Society of Cardiology. The primary results from SEQUOIA-HCM were also presented in the same Late Breaking Clinical Trial session at the Congress and simultaneously published in the New England Journal of Medicine Aficamten Demonstrates Predictable Dosing with No Dose Interruptions Due to LVEF less than50%: Results from prespecified analyses from SEQUOIA-HCM on dosing and measures of safety during treatment with aficamten were presented by Caroline Coats, M.D., Ph.D., Lead Clinician, West of Scotland Inherited Cardiac Conditions Service, Honorary Senior Lecturer, School of Cardiovascular and Metabolic Health, University of Glasgow. In SEQUOIA-HCM, there were no major adverse cardiovascular events associated with treatment with aficamten. Serious adverse events occurred in 8 patients in the aficamten group and 13 patients in the placebo group, none of which were determined to be related to study drug. There was no difference in the incidence of adverse events by dose strength. Over the duration of the 24-week double-blind treatment period, patients treated with aficamten had a placebo-corrected average change in left ventricular ejection fraction of -4.8%. This modest reduction in LVEF in patients treated with aficamten resulted in large reductions in left ventricular outflow tract gradient. Titration of patients to their individually determined target dose of aficamten resulted in dose-related increases in plasma drug concentrations with the majority of patients achieving one of the two highest doses. Following the completion of dose titration, during the maintenance phase, plasma drug concentrations of aficamten remained stable with low variability for the duration of the treatment. Overall, there was a low frequency of LVEF less than50% in SEQUOIA-HCM. LVEF determined by the core laboratory was the prespecified analysis; 5 patients on aficamten compared to 1 patient on placebo had LVEF less than50%. One of the 5 patients on aficamten had LVEF less than40% following infection with COVID-19 but did not interrupt treatment as the site-read LVEF remained greater than 40% and the patient did not have symptoms of heart failure due to systolic dysfunction. Overall, there were no instances of worsening heart failure or treatment interruptions due to low LVEF To enable same-day dose adjustments, the dosing algorithm in SEQUOIA-HCM used site-interpreted LVEF and LVOT gradients for dose adjustments per protocol as implemented by the interactive Web-response system. There were 7 patients treated with aficamten who underwent per-protocol dose reductions for site-read LVEF less than50%. Only one patient treated with aficamten had both core laboratory and site-read LVEF less than50%. There were no dose interruptions and none of the patients treated with aficamten experienced symptoms of heart failure due to systolic dysfunction. Aficamten Improved Novel Integrated Exercise Performance Metric; Improvements in Exercise Performance Correlated with Improvements in Cardiac Structure and Function: Results from a prespecified analysis of cardiopulmonary exercise testing metrics in SEQUOIA-HCM were presented by Gregory Lewis, M.D., Jeffrey and Mary Ellen Jay Chair and Section Head, Heart Failure Medical Director, Cardiopulmonary Exercise Testing Laboratory, Professor of Medicine, Harvard Medical School. In addition to significantly improving peak oxygen uptake, this prespecified analysis demonstrated that treatment with aficamten for 24 weeks improved a novel integrated exercise performance metric. Additionally, improvements in pVO2 were highly correlated with improvements in other clinically important measures. To capture both maximal and submaximal exercise performance an integrated CPET Z-score metric was developed that combines the two measurements into a composite endpoint. It integrates the effect of aficamten on exercise across the entire test, representing a more complete view of the therapeutic effect of aficamten on functional capacity. Aficamten substantially improved overall performance of the integrated CPET Z-score by a placebo-adjusted difference of 0.35. Additionally, of patients treated with aficamten, 72.2% experienced an improvement in pVO2, compared to 43.8% of patients treated with placebo. Among the patients treated with aficamten, 27.8% had a large improvement in pVO2, 21.8% had a moderate improvement and 22.6% had a small improvement. Furthermore, enhanced exercise performance was shown to be correlated with improvements in clinically important measures including Kansas City Cardiomyopathy Questionnaire Clinical Summary Score, New York Heart Association Functional Class, resting LVOT-G, Valsalva LVOT-G, NT-proBNP and high-sensitivity cardiac troponin I. Importantly, these correlations demonstrate that the therapeutic effects of aficamten manifest broadly and are interrelated.

09:40 EDT GameStop trading resumes

09:38 EDT Autolus files to delay quarterly report, cancels earnings call - Autolus Therapeutics announced that it intends to file a notification of late filing with the Securities and Exchange Commission later this week with regard to its quarterly report for the quarter ended March 31, 2024. The filing will allow the company an automatic extension of five additional calendar days to file report, which is due on May 15. In accordance with today's announcement, the company is canceling its previously announced earnings release and call scheduled for before U.S. market open on May 14.

09:35 EDT American Battery ramps up lithium-ion battery recycling facility - American Battery Technology Company has achieved a significant milestone by demonstrating a fixed duration operation of its commercial-scale lithium-ion battery recycling facility at a steady-state throughput of greater than 115% of its maximum design rate. At full production capacity, this facility was initially designed to nominally process 20,000 metric tonnes per year of battery feedstock, and surpassing this design rate demonstrates the impact of the continued process enhancements that have been implemented in the commissioning of the facility. American Battery Technology Company employees load lithium-ion batteries for processing at its recycling plant in Nevada. The company is making significant advancements in commercializing its internally-developed, first-of-kind, battery recycling technologies for recovery of battery materials with high yields, low cost, and a low environmental footprint. The ABTC recycling facility utilizes a first-of-kind integrated set of recycling processes based on a strategic de-manufacturing approach that utilizes a deconstruction process combined with a targeted selective hydrometallurgical process. This system is agnostic to feedstock form factors and can process lithium-ion batteries and manufacturing scrap of a variety of sizes and shapes, and with a wide range of internal chemistries. The first phase of the recycling process produces recycled products that includes copper, aluminum, steel, a lithium intermediate, and a black mass intermediate material, and the integrated second phase further refines these materials into battery grade nickel sulfate, cobalt sulfate, manganese sulfate, and lithium hydroxide. The company is already in the process of implementing the second phase of this integrated recycling facility, where the lithium intermediate from its first phase process will be further refined into a battery grade lithium hydroxide product, and the black mass intermediate material will be further refined into battery grade nickel, cobalt, manganese, and lithium hydroxide products.

09:33 EDT UroGen Pharma trading halted, volatility trading pause

09:30 EDT Microsoft to invest EUR 4B to expand cloud, AI infrastructure in France - During Choose France summit, Microsoft announced its largest investment in France in its 41-year history in the country. This broad investment package is designed to accelerate the adoption of artificial intelligence and cloud technologies, increase the country's competitiveness by fostering digital technology made in France and create long-term benefits for the French economy and job market, the company said. With these investments, Microsoft is directly contributing to France's National Strategy for AI and aligns with the recent recommendations of the French Commission for Artificial Intelligence, to position France as a leader in the development and usage of artificial intelligence. "This major investment demonstrates a steadfast commitment to supporting digital innovation and economic growth in France," said Vice Chair & President of Microsoft Brad Smith. "We are building state-of-the-art Cloud and AI infrastructure, training people with AI skills, and supporting French startups as they use our technology with confidence to grow in a fair and responsible way." Microsoft will invest EUR 4Bn to expand its next generation Cloud and AI infrastructure in France and bringing up to 25,000 of the most advanced GPUs to the country by end of 2025. Microsoft will expand its datacenter footprint across existing sites in Paris and Marseille regions and will also invest in planning a new datacenter campus in the Grand Est Region, in Mulhouse Alsace Agglomeration. Microsoft will operate its AI services and infrastructure in accordance with industry-leading responsible AI and environmental sustainability practices. The company has adopted a Responsible AI Standard for its own AI platforms and services, and it has established an AI Assurance Program to share best practices and promote responsible AI practices more broadly. Microsoft is coupling its infrastructure investment with a renewed focus on skilling at scale. It will support skilling for 1 million people to help the country embrace the new AI era, with a specific focus on job seekers, students, SMBs and professional audiences. Microsoft is partnering with Kokoroe, a French Ed-Tech company specialized in micro-learning to build this new exclusive content, based on short and easy-to-consume modules, with no technical background required. The third aspect is that Microsoft announces new initiatives to supporting the French startup ecosystem and embracing France's ambitions to develop leading and high growth AI businesses.

09:17 EDT GoPro announces retail expansion at Best Buy - GoPro (GPRO) announced a large-scale merchandising rollout and sales program at Best Buy (BBY). The retail expansion combines the installation of completely redesigned product displays, an assisted sales program, and in-store and digital marketing. GoPro cameras and accessories will be featured in new products displays in nearly 900 Best Buy stores across North America, including more than 250 specialty Camera Experience Shops. Best Buy store associates will also be specially trained on GoPro's complete product lineup. The new expanded product displays are now in the Best Buy Camera Experience Shops and will be added to remaining Best Buy locations in July.

09:09 EDT Scilex provides information of short selling of stock - Scilex Holding provides information to its stockholders regarding short selling of Scilex common stocks traded on the Nasdaq Capital Market. According to credible information available to Scilex, Scilex management believes there are approximately 10 million share of Scilex common stock being sold short and additionally, there are more than 10 million Dividend Shares deemed to have been sold as "naked short" positions on or after January 2023 that have not been covered as of today. The Company believes that there are substantial "naked short" positions in approximately 44 million shares of its common stock that had not cast votes based on the reports tabulated by Broadridge Financial Solutions, Inc., an independent third party that collects and tabulates stockholder votes, for the Company's prior two annual meetings for its stockholders. The practice of manipulative or abusive "naked short" selling or maintaining "naked short" positions may constitute a violation of SEC Regulation SHO. Scilex Management is determined to combat manipulative and illegal short selling of Scilex common stock which has the effect of reducing shareholder value and infringing on shareholders' rights.

09:08 EDT Gray Television partners with AAPB to bring games to Midwestern markets - Gray Television announces an agreement to bring select American Association of Professional Baseball, AAPB, games to free, over-the-air local television stations in multiple Midwestern markets and across three of Gray's local sports networks: Arizona Family Sports in Arizona, Peachtree Sports Network in Georgia, and Silver State Sports and Entertainment Network in Nevada. The AAPB is a Professional Partner League of Major League Baseball. "Gray is committed to live sports," said Sandy Breland, Gray's Chief Operating Officer. "This agreement provides another example of ways we are providing viewers what they want with live sports."

09:07 EDT Data Storage announces expansion into UK, opens London office - Data Storage announced the expansion of its CloudFirst subsidiary into the United Kingdom, UK, with the opening of its London office. This strategic expansion marks a significant milestone in the Company's strategy to serve a global clientele and further CloudFirst's presence in key global markets.

09:06 EDT MoneyHero appoints Qian as Chief Financial Officer - MoneyHero announced the appointment of Hao Qian as the Company's new permanent Chief Financial Officer, CFO, effective immediately. Reporting directly to MoneyHero's Chief Executive Officer, CEO, Rohith Murthy, and the Company's Board of Directors, Qian will be based at MoneyHero's headquarters in Singapore.

09:05 EDT Cadiz's ATEC Water Systems awarded $5.2M contract - Cadiz is pleased to announce that the company's water treatment operating subsidiary ATEC Water Systems, a producer of specialized water filtration solutions for groundwater, was the successful bidder to supply water treatment filtration systems for the Cascade Groundwater Alliance treatment project in Gresham, Oregon. Under the terms of the award, ATEC will manufacture 140 filters to remove manganese from local groundwater for a total gross contract value of approximately $5.2M. The filters are anticipated to be delivered over the next 12 months.

09:04 EDT DaVita appoints Madhu Narasimhan as Chief Information Officer - DaVita appointed Madhu Narasimhan as Chief Information Officer, effective June 3. Narasimhan previously served as the Global Head of Innovation for Wells Fargo and led product, technology, and enterprise clinical systems for Kaiser Permanente.

09:04 EDT Avalara expands partnership with Shopify - Avalara, a provider of cloud-based tax compliance automation for businesses of all sizes, announced that it has expanded its partnership with Shopify by joining the Shopify Tax Platform. Through the expanded partnership, Shopify merchants of any size can easily manage and automate global tax compliance with Avalara.

09:02 EDT Arthur J. Gallagher acquires Acumen Advisors - Arthur J. Gallagher acquired Cedar Rapids, Iowa-based Acumen Advisors. Terms of the transaction were not disclosed. Acumen is an employee benefits consultant serving small and mid-size businesses throughout Iowa. Andrew Morf, Kirby Moss and their team will remain in their current locations under the direction of Tom Lannen, head of Gallagher's Midwest region employee benefits consulting operations.

08:55 EDT LPL Financial: Noble Traditions joins broker-dealer, RIA, custodial platforms - LPL Financial announced that financial advisor Garrett Oczachowski has joined LPL Financial's broker-dealer, RIA and custodial platforms. He reported serving approximately $280 million in advisory, brokerage and retirement plan assets* and joins LPL from JPMorgan Chase. Based in Santa Monica, Calif., Oczachowski is a 25-year veteran of the financial services industry. Specializing in retirement income planning, he is dedicated to helping clients create sustainable income streams and navigate the complexities of retirement. He also provides support in investment management, risk management and estate planning.

08:54 EDT Outlook Therapeutics submits ONS-5010 MMA to MHRA for Wet AMD - Outlook Therapeutics announced the submission of its Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency in the United Kingdom seeking authorization of ONS-5010/LYTENAVA for the treatment of wet age-related macular degeneration. The submission was completed under the new International Recognition Procedure, which allows the MHRA to rely on a positive opinion by the European Medicines Agency's CHMP concerning an application for grant of marketing authorization for the same product in the EU. The IRP is available for new UK MAAs of a medicinal product that has previously been authorized by a Reference Regulator. In this case this is the EMA. The MAA submission is supported by results from Outlook Therapeutics' wet AMD clinical program for ONS-5010, which consists of three completed registration clinical trials - NORSE ONE, NORSE TWO and NORSE THREE.

08:46 EDT Monogram Orthopaedics engages CRO to oversee mBos clinical trial activities - Monogram Orthopaedics has engaged a global Contract Research Organization to oversee its clinical trial activities for its mBos Total Knee Arthroplasty System and represent its submission to the local regulators outside the United States. The transnational CRO, which the Company cannot disclose due to competitive reasons, has extensive experience and successful FDA submissions from clinical investigations conducted Outside the United States. Currently, the company is targeting approximately 100 TKA surgeries at three sites, with three months of follow-up and a 25% reduction in safety event rates. This strategy could save the company significant costs and time, estimated at $1.5M for the trial. Monogram intends to conduct the multi-center Total Knee Arthroplasty clinical trial with the mBos TKA System using the cemented version of its FDA-cleared mPress TKA implant. Monogram anticipates that once approved, the centers will have sufficient volume to complete enrollment and study execution expeditiously. Monogram developed the clinical trial study design considering FDA guidance and regulations for clinical investigations conducted outside the United States. Good clinical practice guidelines will be followed, including review and approval by an independent ethics committee and informed consent from subjects. The clinical trial will be conducted to meet the FDA and local regulatory requirements on research with human subjects, Health and Human Services Regulations on research with human subjects, ISO 14155:2011, and ICH's Good Clinical Practices guidelines. The future clinical study report will include the supporting information outlined in 21 CFR 812.28.

08:43 EDT Catheter Precision announces orders from UCLA medical center, Rady Children's - Catheter Precision announced additional product evaluations for its newest product, LockeT. As previously announced, the company has recently expanded their US sales and clinical team in preparation for the national product launch of LockeT.

08:41 EDT OSI Systems gets $9M to provide cargo and vehicle inspection systems - OSI Systems announced that its Security division received an order from an international customer for approximately $9M to provide the Company's Eagle M60 high energy mobile cargo and vehicle inspection systems including related service and support. This order represents the initial fulfillment under a multi-year framework agreement between the Company and the customer, setting the stage for future supply of additional solutions. OSI Systems' Chairman and CEO, Deepak Chopra, commented, "We are proud to receive this award to deploy one of our leading cargo and vehicle inspection systems. We are committed to helping our customers in their efforts to enhance border checkpoint safety and security."

08:40 EDT Ascendis announces 2-year results from post-hoc analysis of Phase 3 trial - Ascendis Pharma announced 2-year results from a post-hoc analysis of the Company's Phase 3 PaTHway Trial demonstrating significant and sustained improvements in renal function in adults with chronic hypoparathyroidism treated with TransCon PTH. The data were shared in an oral presentation on May 12 by Peter Schwarz, M.D., Professor of Clinical Medicine at the University of Copenhagen, during the European Congress of Endocrinology 2024, the annual meeting of the European Society of Endocrinology. The post-hoc analysis examined the impact of treatment with TransCon PTH on renal function using estimated glomerular filtration rate through Week 104 of PaTHway, a Phase 3 double-blind, placebo-controlled trial of 82 dosed adults with chronic hypoparathyroidism randomized 3:1, with a 26-week blinded period followed by an ongoing 156-week open-label extension period. Across both treatment arms, TransCon PTH treatment resulted in a mean eGFR increase of 8.9 mL/min/1.73m2 from baseline at Week 52, sustained at Week 104 with a mean change from baseline of 9.0 mL/min/1.73m2. Treatment was generally well-tolerated, with no new safety signals

08:39 EDT Corporacion America Airport announces recent development - Corporacion America Airports a private airport operator, announced the following recent development related to the arbitration procedure request submitted by Sociedad Aeroportuaria Kuntur Wasi in which CAAP holds 50% of the shares, to the competent authority, ICSID, known as CIADI in Spanish, in June 2018, in connection with the unilateral decision of the Government of Peru to terminate the concession agreement for the new Chinchero International Airport. On May 9 Kuntur Wasi received notification from the ICSID Arbitral Court of the award regarding the arbitration procedure on the case Sociedad Aeroportuaria Kuntur Wasi S.A. and Corporacion America v. Republic of Peru. The Tribunal decided, among other things that "Peru breached the Concession Contract by terminating it without a well- founded reason of public interest". Furthermore, "the Tribunal orders that damages in the amount of US$91,205,056 should be paid to Kuntur Wasi, together with any additional interest that has accrued at the rate established in this award to the date of payment; compounded annually". The Company will provide any further updates on the matter as appropriate

08:38 EDT Safety Shot enters collaboration with Gopuff - Safety Shot announced its collaboration with Gopuff to give Safety Shot, easy accessibility to millions of consumers nationwide. Starting in May, Safety Shot will launch a comprehensive 360-degree marketing campaign in support of Gopuff offering the revolutionary product in convenient 4-packs and singles.

08:37 EDT Alpha Tau announces Alpha DaRT treatment of first patient with liver cancer - Alpha Tau Medical announced that its first patient with liver cancer metastases has been treated in a feasibility and safety study of Alpha DaRT at the McGill University Health Center in Montreal, Canada. The trial seeks to recruit up to 10 patients who are eligible for a two-staged hepatectomy to resect liver metastases of colorectal cancer. The study primarily aims to examine the feasibility of delivering Alpha DaRT sources into the liver metastases, as well as the safety of utilizing the Alpha DaRT sources in the liver by assessing the frequency and severity of related adverse events. The study also aims to examine Alpha DaRT's efficacy in terms of radiological response, assessed after insertion of the Alpha DaRT sources, and via pathological response, assessed after the second stage of surgery

08:35 EDT Maxeon Solar to postpone release of Q4, Q1 results - Maxeon Solar Technologies announced it will postpone the release of its Fourth Quarter, Fiscal Year 2023 and First Quarter 2024 Financial Results, previously scheduled for May 15, 2024 U.S. ET / May 16, Singapore Time, to May 23, 2024. The additional time is necessary to complete the company's preparation of its annual and quarterly reports and to provide the market with a comprehensive business update.

08:34 EDT Transcode Therapeutics board issues letter to shareholders - The Board and Management of TransCode Therapeutics issued the following open letter to shareholders of the Company: "As you may have seen, we have filed an amended proxy statement in connection with our Annual Meeting scheduled for June 13. One of the proposals in the proxy provides for authorizing the Board of Directors, if they believe it is the best interests of the company and shareholders, to effect a reverse split of our stock. This has been one of the most difficult deliberations we have had. This is NOT something any of the directors wishes to do - and hopes that it won't be needed. The reason for the requested authorization is that our common stock did not close at $1.00 per share or more for any ten day period ended May 6, the so-called Minimum Bid Requirement.... Our stock has closed above $1.00 per share for four consecutive days through May 10. Even if it continues to close above $1.00 per share for another six trading days, it will not guarantee that the Panel will provide any leeway. The reason for requesting the authority to do the reverse split is that, as a last resort, we can inform the Panel that shareholders have authorized a reverse split. There is also no assurance that the authorization will result in our stock not being delisted, but the company and its advisors believe this is our best chance... We hope to not have to effect a reverse split, but we also believe that our shareholders are best served by doing everything we can to continue to be Nasdaq-listed."

08:33 EDT Kyndryl Holdings divesting SIS transaction processing platform - Kyndryl has entered into a definitive agreement to divest its transaction processing platform for the securities brokerage industry in Canada, known as Securities Industry Services or SIS, to Broadridge Financial Solutions. Kyndryl intends to provide managed services and capabilities to Broadridge related to SIS following the divestiture. Revenues generated by both Skytap and SIS over the last twelve months were less than 1% of Kyndryl's annual revenue. While Kyndryl expects to record a transaction-related gain in conjunction with the SIS divestiture, the transactions have no impact on Kyndryl's FY25 outlook. The company intends to use the net proceeds from the two transactions for general corporate purposes. Terms of the transactions were not disclosed. Closing of the SIS transaction is subject to customary closing conditions, including required regulatory approvals.

08:31 EDT Kyndryl Holdings acquires privately held Skytap - Kyndryl has acquired privately held Skytap, a specialized workload services provider. Kyndryl's acquisition of Skytap aims to expand the company's hybrid cloud services portfolio. Skytap's innovative technologies will be combined with Kyndryl's expertise in helping customers utilize cloud native services to accelerate the adoption of advanced analytics, artificial intelligence and development, security and operations. Skytap's technologies enable customers to move and run their mission-critical systems in the public cloud with minimum change.

08:26 EDT Ocean Power announces renewable energy production milestone - Ocean Power Technologies announced it is approaching 15MWh of renewable energy production from its family of PowerBuoys. The recent launch of its Next Generation PB off the coast of New Jersey has materially accelerated average energy production by combining solar, wind, and wave energy production capabilities. Philipp Stratmann, CEO and President of OPT, expressed his enthusiasm about this milestone, stating, "These numbers show that non-grid connected marine energy production is not just for the R&D community, but is a commercially available solution. Charging USVs, monitoring the marine environment, including during whale migration season, and supporting the defense and security industry is all possible. We have worked with customers in defense, offshore wind, oil and gas, and general ocean sciences and look forward to announcing more deployments."

08:25 EDT Senti Bio announces first patient dosed in Phase 1 trial of SENTI-202 - Senti Biosciences announced that patient dosing has commenced in the Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia, AML. AML is a cancer of the blood and bone marrow and is the most common type of acute leukemia in adults. Initial efficacy data is anticipated by year-end 2024 and initial durability data following in 2025. "Launching the Phase 1 clinical trial of SENTI-202 marks an important step forward in our mission to redefine the standard of care for patients with AML, offering hope where options are scarce and outcomes are dire. By systematically engineering SENTI-202 to address the complexities of AML heterogeneity while safeguarding healthy marrow cells, we aim to address the critical limitations of existing therapies," said Kanya Rajangam, MD, PhD, Head of Research & Development and Chief Medical Officer of Senti Bio. "This milestone underscores our unwavering commitment to advancing our clinical program for the betterment of patients, and we eagerly anticipate the potential impact SENTI-202 may have in transforming the lives of people with cancer."

08:23 EDT Biomerica announces inFoods IBS pilot launch - Biomerica announced the initiation of a pilot program for its inFoods IBS product with a large 1,100-member physician group. This pilot launch will commence in June 2024. inFoods IBS offers a novel approach by identifying individual patient specific dietary triggers for IBS symptoms, which could revolutionize management of the condition. This technology has demonstrated remarkable success in alleviating symptoms for the majority of patients participating in the most extensive clinical study of its kind. The inFoods IBS product has undergone rigorous testing in a prospective, double-blind, placebo-controlled endpoint study conducted at prestigious institutions including the Mayo Clinic, Beth Israel Deaconess Medical Center, Houston Methodist Hospital, and the University of Michigan. The study results revealed a significant improvement in Abdominal Pain Intensity scores for IBS patients in the treatment diet arm compared to those in the placebo diet arm. Notably, this study found that the majority of IBS patients experienced remarkable relief with inFoods IBS.

08:22 EDT Avaya, RingCentral expand strategic partnership with AI- driven collaborations - RingCentral, a provider of AI-driven cloud business communications, contact center, video and hybrid event solutions, and Avaya, 'a global leader in customer experience and communications solutions," announced an expansion of offerings for Avaya customers, including a new hybrid solution of RingCentral's AI-powered cloud business communications solution with Avaya Aura telephony, providing enhanced collaboration capabilities. This new hybrid offering allows users within the same organization to seamlessly collaborate with each other, whether individuals are using Avaya Aura or Avaya Cloud Office telephony solutions. Customers gain additional value from their existing investments in Avaya's solutions by combining them with RingCentral's video calling and messaging features, including RingSense(TM) AI -- RingCentral's core AI platform. This hybrid solution, which is exclusively available through this partnership, also provides Avaya's enterprise customers with the choice to utilize their existing Avaya Aura Platform or cloud-based Avaya Cloud Office by RingCentral ACO for call control functionality, enabling a seamless user experience across messaging, video and phone.

08:21 EDT JinkoSolar delivers over 1.1M Tiger Neo modules to German solar power plant - JinkoSolar has delivered its Tiger Neo modules to a Solar Power Plant in Lobstadt, Germany: the Witznitz Solar Park. JinkoSolar has delivered more than 1.1 million Tiger Neo modules to the site. Shell Energy Europe has signed a 15-year Power Purchase Agreement. The Witznitz Solar Park project is to date the biggest PV Project in Germany and one of the largest in Europe.

08:20 EDT Axalta Coating to acquire The CoverFlexx Group for initial $285M consideration - Axalta Coating Systems has entered into a definitive agreement to acquire The CoverFlexx Group from Transtar Holding Company for initial cash consideration of $285 million, plus an additional $10 million earnout based on the business's 2024 performance. Closing is expected to occur in the third quarter and is subject to regulatory approval and other customary closing conditions. The CoverFlexx Group manufactures and sells coatings for automotive refinish and aftermarket applications, focused on economy customers in North America. The business offers a wide range of primers, basecoats and clearcoats, as well as aerosols, fillers, bedliners, detailing products and paint shop accessories. Established brands of The CoverFlexx Group include Transtar Autobody Technologies, Pro Form and Aftermkt Armor products. The CoverFlexx Group had revenue of $78 million in 2023 with operations that include more than 120 employees and manufacturing and product development sites in Brighton, Michigan and Milton, Ontario.

08:18 EDT Redwire developing European-built VLEO spacecraft platform dubbed Phantom - Redwire announced Phantom, a new European Very Low Earth Orbit, VLEO, spacecraft platform. Phantom is being developed at Redwire's facility in Belgium and is designed to carry out a wide array of intelligence, Earth science, and communications missions. Phantom joins Redwire's American-built VLEO spacecraft platform, SabreSat, that was recently unveiled. Redwire's Phantom European VLEO Platform. Image: RedwirePhantom, like its American counterpart, is intended to fill many different roles in a reliable and cost-effective way. Leveraging over four decades of heritage in satellite design, development and in-orbit operations, Phantom has an aerodynamic design that reduces propellant requirements, and could allow the satellite to stay in VLEO for up to five years. The design also uses standardized off-the-shelf hardware to reduce manufacturing costs and, with a total anticipated spacecraft mass of less than 300 kg, is compatible with existing small satellite launchers

08:17 EDT Axalta Coating to acquire automotive coatings company CoverFlexx - Axalta Coating has signed a definitive agreement to acquire The CoverFlexx Group. The transaction is anticipated to close in Q3, pending regulatory approval and customary closing conditions. The CoverFlexx Group, a subsidiary of Transtar Holding, specializes in manufacturing and distributing coatings for automotive refinish and aftermarket applications. The CoverFlexx Group operates with a workforce of over 120 employees across manufacturing and product development facilities located in Brighton, Michigan, and Milton, Ontario.

08:16 EDT Collegium Pharmaceutical announces $35M accelerated share repurchase program - Collegium Pharmaceutical announced that it has entered into an Accelerated Share Repurchase agreement with Jefferies to repurchase $35M of the Company's common stock. Collegium will execute the ASR as part of the $150M share repurchase program authorized by its Board of Directors in January 2024. Upon completion of this ASR, Collegium will have $115M remaining under the program. Under terms of the agreement, Collegium will pay $35 million to Jefferies and will receive an initial delivery of 888,889 shares, based on the $31.50 closing stock price of Collegium's common stock on May 10, 2024, representing approximately 80% of the total shares the Company expects to repurchase under the ASR agreement. The final number of shares repurchased will be based on the volume-weighted average prices of Collegium's common stock during the term of the ASR and subject to adjustments related to the terms and conditions of the ASR agreement. The final settlement of the ASR is expected to be completed in the third quarter of 2024. As of March 31, 2024, Collegium had approximately 32.7 million shares outstanding.

08:14 EDT IN8bio presented data on gamma-delta T cell manufacturing platform - IN8bio presented in an oral session details about its robust and reproducible proprietary clinical-scale gamma-delta T cell manufacturing platform across different donor populations, at the American Society of Gene & Cell Therapy, ASGCT, 2024 Annual Meeting. "The data presented provide additional insight on the complex gene-expression changes that occur throughout the manufacturing of our gamma-delta T cell products, which demonstrate a consistent profile at the end of manufacturing," said Dr. Kate Rochlin, Chief Operating Officer of IN8bio. "These new insights into the potency, effector functions, and trafficking changes that occur from initiation to the end of manufacturing in our gamma-delta T cells underscores the reproducibility and robustness of our manufacturing process. The data suggests that the characteristics of the final product are driven more by the manufacturing process than individual donor profiles. We seek to understand how key molecular characteristics allow the optimization of these unique therapies for potentially improved clinical outcomes."

08:13 EDT CareCloud board declines unsolicited, non-binding indication of interest - CareCloud released details regarding its receipt of an unsolicited, non-binding indication of interest dated March 4, 2024, to acquire the Company for $5.00 per share of its common stock, and the $25 redemption price per share of its 8.75% Series B Cumulative Redeemable Perpetual Preferred Stock. The indication of interest was subject to satisfactory due diligence. The letter made no mention of the treatment of the Company's 11% Series A Cumulative Redeemable Perpetual Preferred Stock, which the Company believes was due to their respective redemption provisions on a change of control that enables a buyer to take the Company private while leaving the Series A Preferred Stock as a publicly traded security. The Company's Board of Directors thoroughly evaluated the indication of interest and determined it was in the Company's best interests to decline it in its present form. Prompted by the indication of interest, the Company retained an investment bank to examine and evaluate the terms of its Series A Preferred Stock, including the differing redemption rights afforded to Series A preferred stockholders as compared to Series B preferred stockholders, and to make recommendations to the Board of Directors that may be beneficial to the Company and its shareholders.

08:09 EDT Barinthus Biotherapeutics sees cash runway into 4Q25 - As of March 31, 2024, cash, cash equivalents and restricted cash was $130.0 million, compared to $142.1 million as of December 31, 2023. The cash used in operating activities was $11.8 million in the first quarter of 2024, primarily resulting from development of our pipeline and ongoing clinical trials. Based on current research and development plans, the Company expects its cash runway to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2025.

08:09 EDT TriLink Bio teams with Johns Hopkins on RNA innovation center - TriLink BioTechnologies , a Maravai LifeSciences company and global provider of life science reagents and services, is collaborating with the Johns Hopkins University to accelerate transformational research in RNA therapeutics and discovery. A new center within the Johns Hopkins Whiting School of Engineering will accelerate research and therapeutic development, leveraging TriLink's leading RNA synthesis technology. TriLink's investment includes direct funding for the center and access to TriLink's proprietary in vitro transcription technology, CleanScript(TM), which will enable Hopkins researchers to advance mRNA development. Additionally, TriLink will provide technical expertise and access to other critical discovery and manufacturing supplies, further lowering the barriers to discovery and application. "The collaboration with Johns Hopkins reinforces our commitment to advancing nucleic acid-based therapies," commented Drew Burch, President, Nucleic Acid Products, Maravai LifeSciences. "Our participation in this center of excellence allows TriLink to share its deep knowledge and expertise in nucleic acid production, helping to enable these researchers at Hopkins with the tools they need to develop advanced therapies to treat patients."

08:07 EDT Rand Capital increases quarterly dividend 16% to 29c per share - Rand declared its regular quarterly cash dividend distribution of 29c per share, which was increased by 4c per share or 16%. The cash dividend will be distributed on or about June 14 to shareholders of record as of May 31.

08:06 EDT LivePerson, Avaya announce new partnership - Avaya and LivePerson announced a new partnership designed to unify voice, digital, and AI capabilities into a single omnichannel solution that delivers connected, personalized customer experiences and accelerates enterprise digital transformation. The Avaya and LivePerson partnership enables enterprises to augment their existing investments in Avaya cloud and premises-based solutions by deploying market-leading digital, automation, AI, and analytics capabilities in an integrated experience - no rip-and-replace or migration required - enabling transformative outcomes faster with lower cost and substantially less risk to operations. As part of the new partnership, Avaya will integrate LivePerson's award-winning Conversational Cloud platform for digital customer conversations and conversational intelligence to power two new, innovative offerings: Advanced Digital Capabilities offers dozens of digital channels, leverages LivePerson's best-in-class messaging, AI, and conversation orchestration solutions, and natively supports third-party channels, bots, and LLMs. It will be fully integrated with Avaya Experience Platform(TM) premises-based, private cloud, and public cloud contact center solutions, creating a connected employee experience with Avaya's unified agent desktop. Unified Insights Capabilities unlocks voice of the customer data from all channels so enterprises can measure outcomes through both near real-time and post-conversation insights. This suite of capabilities takes invaluable data from customer interactions and makes it available for the rest of the business to improve processes, inform R&D,and drive strategy. The new solution leverages LivePerson's conversational intelligence suite, including Analytics Studio.

08:05 EDT GRI Bio expects cash to fund operations into Q3 of 2024 - As of March 31, 2024, the Company had cash and cash equivalents of approximately $4.1 million. Based on the Company's current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the third quarter of 2024. "We continue to execute on both the clinical and corporate fronts. Our team is working diligently to drive our Phase 2a biomarker study in IPF toward interim data readout which we believe will provide valuable insight for our development program moving forward," commented Marc Hertz, PhD, Chief Executive Officer of GRI Bio. "On the corporate side, we continue to bolster our patent estate as well as actively engage with and present at scientific meetings which we believe underscore the potential of GRI-0621. We are committed to building a growing body of data and believe we are positioned to unlock significant value in 2024."

08:04 EDT Exagen sees FY24 revenue at least $55M, consensus $54.16M - For full year 2024 revenue, the company is increasing its guidance to at least $55 million and now believe its adjusted EBITDA will be better than negative $18 million. Given its continued improved performance, the company believes its existing cash and cash equivalents are adequate to meet its anticipated cash requirements into 2026.

08:02 EDT Compass Therapeutics sees cash runway into late 2026 - As of March 31, 2024, cash and marketable securities were $156.3 million as compared to $152.5 million as of December 31, 2023, extending our cash runway into late 2026.

07:53 EDT Amazon's Zoox being investigated for unexpected sudden braking - Zoox, a subsidiary of Amazon developing autonomous vehicles, is being investigated by the National Highway Traffic Safety Administration over "unexpected sudden braking" that could lead to rear-end collisions. The Office of Defects Investigation has received notice of two incidents involving Zoox vehicles equipped with the Zoox automated driving system wherein the vehicles unexpectedly braked suddenly, leading to rear-end collisions. Each incident involved a Toyota Highlander equipped with Zoox ADS. Reference Link

07:42 EDT MiNK Therapeutics appoints Yekaterina Chudnovsky as board observer - MiNK is pleased to announce the appointment of Yekaterina Chudnovsky as Board Observer. An accomplished attorney and venture investor, Ms. Chudnovsky brings a wealth of experience as a dedicated patient advocate and supporter of medical research. She currently serves as the Chairperson of the GI Research Foundation at the University of Chicago Digestive Diseases Center.

07:39 EDT Enovix begins customer sampling of EX-1M batteries - Enovix Corporation announced that it has begun customer sampling of its breakthrough EX-1M battery. Initial EX-1M samples were built and tested at the company's facility in Fremont for IoT and smartphone customers. Enovix plans to build a larger number of EX-1M samples from its Agility Line at Fab2 in Malaysia later in the second quarter of 2024. "We set out on an ambitious plan last year to build a battery that would meet the demanding requirements of leading smartphone customers," said Dr. Raj Talluri, President and CEO of Enovix. "With EX-1M now sampling, we are ushering in a new era of lithium-ion battery technology by utilizing a 100% active silicon anode to boost energy density and allow customers to keep up with a growing array of energy needs with the onset of AI."

07:39 EDT BridgeBio presents additional data, analyses from Phase 3 ATTRibute-CM study - BridgeBio Pharma announced positive results of four new analyses from its Phase 3 ATTRibute-CM study of acoramidis in ATTR-CM at the European Society of Cardiology, ESC, Heart Failure Congress 2024. ATTRibute-CM was designed to study the efficacy and safety of acoramidis, an investigational, next-generation, orally-administered, highly potent, small molecule stabilizer of TTR. Key results included: In a pre-specified sensitivity analysis applied to the entire ITT population, acoramidis significantly reduced all-cause mortality as assessed by the Cochran-Mantel-Haenszel test; In high-risk participants with Stage 4 CKD, acoramidis treatment was associated with 25% relative risk reduction in deaths at Month 30 versus placebo, consistent with the observations in the modified intention-to-treat population; No safety signals of potential clinical concern were identified

07:37 EDT Verrica Pharmaceuticals sees cash runway into 1Q25 - As of March 31, 2024, Verrica had cash and cash equivalents of $48.9 million. Verrica believes that its existing cash and cash equivalents as of March 31, 2024 will be sufficient to support planned operations into the first quarter of 2025.

07:33 EDT Titan Medical reports cash balance of $5.7M as of March 31 - As of March 31, 2024, Titan had cash of $5.7 million, compared to $7.5 million as at December 31, 2023. Working capital was $4.4 million as of March 31, 2024, compared to $5.5 million as at December 31, 2023. On March 18, 2024, the Company announced it has entered into a definitive amalgamation agreement with Conavi Medical to combine the companies in an all-stock transaction. Under the terms of the Definitive Agreement, a newly incorporated and wholly-owned subsidiary of the Company and Conavi will amalgamate and the shareholders of Conavi will be issued Common Shares of the Company based on an exchange ratio to be determined pursuant to the Definitive Agreement. The exchange ratio will be adjusted, if necessary, such that the Company's shareholders prior to closing of the Transaction will hold at least 10% of the resulting shares following completion of the Transaction, but may be higher depending on the Company's cash balance on the Transaction closing date. In connection with the Transaction, Titan expects to delist its common shares from the Toronto Stock Exchange and apply to have them listed instead on the TSX Venture Exchange. Titan is focused on the execution of the Transaction, which remains subject to a number of conditions precedent set forth in the Definitive Agreement, including the approval of the Company shareholders, the Conavi shareholders, and the approval of the TSXV for the listing of the Common Shares following closing of the Transaction.

07:27 EDT Incyte announces intention to repurchase up to $2B common stock - Incyte announced that its board of directors approved a share repurchase authorization of $2B. The company has commenced a modified Dutch Auction tender offer to repurchase shares of its common stock for an aggregate purchase price of up to $1.672B. In addition, on May 12, Incyte entered into a separate stock purchase agreement with Julian Baker, Felix Baker, and entities affiliated with Julian and Felix Baker, including funds advised by Baker Bros. Advisors, to repurchase up to $328M of the company's common stock. This would enable the Baker Entities to maintain their current ownership level of approximately 16.4% of Incyte's outstanding common stock. The Baker Entities purchase will be at the same price per share as is determined and paid in the tender offer. Incyte is offering to purchase up to $1.67B in value of its common stock at a price not greater than $60.00 per share nor less than $52.00 per share, net to the seller in cash, less any applicable withholding taxes and without interest, upon the terms and subject to the conditions set forth in the tender offer documents that are being distributed to stockholders. The company reserves the right, in its sole discretion, to change the per share purchase price options and to increase or decrease the aggregate value of shares sought in the tender offer, subject to applicable law. In accordance with the rules of the SEC, Incyte may purchase in the offer up to an additional 2% of its outstanding shares without amending or extending the tender offer. On May 10, the Nasdaq closing price of the common stock was $53.06 per share. The tender offer will expire at 12:00 midnight, at the end of the day, New York City time, on Monday, June 10, unless extended. The company has entered into a stock purchase agreement with the Baker Entities. Under the stock purchase agreement, the Baker Entities have agreed not to tender or sell any shares in the tender offer and instead have agreed to sell to the company, following completion of the offer, a pro rata number of shares based on the number of shares that the company purchases in the offer such that the Baker Entities' aggregate percentage ownership in the company will be substantially equal to the Baker Entities' current levels. The Baker Entities Purchase will be at the same price per share as is determined and paid in the offer and is expected to occur on the 11th business day following the expiration of the offer. The closing of the Baker Entities Purchase is subject to the completion of the offer. Assuming that the offer is fully subscribed, the aggregate purchase price for the shares purchased pursuant to the stock purchase agreement is anticipated to be approximately $328M. The Baker Entities, in the aggregate, own 36,833,933 shares of common stock, representing in the aggregate beneficial ownership of approximately 16.4% of outstanding common stock as of May 9. If the tender offer is fully subscribed, the company would repurchase a total of approximately $2B of its common stock through the tender offer and the stock purchase agreement.

07:26 EDT Encore Capital announces proposed senior secured notes offering - Encore Capital Group announced its intention to offer, subject to market and other conditions, $400M aggregate principal amount of senior secured notes due 2030 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended and outside the United States to non-U.S. persons. The notes will be senior secured obligations of the Company, and will be fully and unconditionally guaranteed on a senior secured basis by substantially all material subsidiaries of the Company. The obligations of the Company and the guarantors will be secured, together with the Company's other senior secured indebtedness, by substantially all of the assets of the Company and the guarantors. The interest rate and other terms of the notes will be determined at the pricing of the offering. The Company intends to use the proceeds from this offering to repay drawings under its revolving credit facility, to pay certain transaction fees and expenses incurred in connection with the offering of the notes and for general corporate purposes. The Company currently intends to use borrowings under the Global Senior Facility or other available sources of financing to redeem its EUR 350M senior secured notes due 2025 on or about October 15, 2024.

07:23 EDT Falco Resources announces opening of Espace Falco - Falco Resources announced the opening of Espace Falco located at 157 rue Principale in Rouyn-Noranda. This new space is dedicated to meeting citizens, groups and organizations wishing to learn about the Falco Horne 5 project. In anticipation of the public examination of the Bureau d'audiences publiques sur l'environnement, Falco invites the population to an information meeting organized by the BAPE as part of the public information period. This information meeting will be held on Tuesday, May 21 at 7:30 p.m. at the Petit Theatre du Vieux-Noranda and will allow the community to learn and ask questions about the Falco Horne 5 Project. Helene Cartier, Vice-President, Environment, Sustainable Development and Community Relations, said: "We look forward to continuing our collaborative approach with host communities and the launch of the BAPE process will open up more consultations and transparent and direct discussions with stakeholders, as well as allowing the advancement of the environmental permit process towards obtaining a ministerial decree authorizing the Falco Horne 5 Project."

07:22 EDT D-Wave and USC renew multiyear deal to advance annealing business solutions - D-Wave Quantum software, and services and the world's first commercial supplier of quantum computers, and the University of Southern California USC announced a renewed multiyear partnership. Under the agreement, the USC Viterbi School of Engineering will continue to house a D-Wave state-of-the-art Advantage quantum computer, facilitating ongoing exploration and adoption of annealing quantum computing solutions for businesses, researchers, and government..The agreement also advances the university's efforts to achieve the research and education objectives of USC President Carol Folt's Frontiers of Computing "moonshot," a more than $1 billion initiative that supports the ethical advancement of technologies such as AI, robotics and quantum computing.

07:21 EDT Entera Bio to present Phase 1 data from EB612 at ENDO 2024 - Entera Bio announced that it has been selected to present data for its investigational program EB612 at the Endocrine Society ENDO 2024 Annual Meeting which will be held on June 1-4, 2024 in Boston, Massachusetts. The EB612 program is being developed by Entera to provide the first oral PTH(1-34) tablet peptide replacement therapy for patients suffering from hypoparathyroidism. Hypoparathyroidism is characterized by deficient PTH production, hypocalcemia and hyperphosphatemia. Standard treatments include several daily administrations of high dose oral calcium supplements and calcitriol, which are often associated with ectopic calcification, including nephrocalcinosis and renal failure. Late stage investigational PTH replacement treatments include TransCon PTH by Ascendis Pharma A/S and eneboparatide by Amolyt Pharma. Both these modalities require patients to administer injections every day.

07:20 EDT Lantronix appoints Gurusamy as CSO - Lantronix announced the appointment of Mathi Gurusamy as its chief strategy officer, CSO, effective May 13, 2024. In his new role, Gurusamy will spearhead the company's strategic planning and execution of growth opportunities, manage merger and acquisition activities, and drive go-to-market strategies that address key IoT technology trends to bolster Lantronix's growth.

07:18 EDT Gildan Activewear publishes investor presentation for 2024 annual meeting - Gildan Activewear announced that it has published an investor presentation, entitled "Successfully Driving Long-Term Value for All Shareholders", in connection with its upcoming 2024 Annual Meeting of Shareholders to be held on May 28, 2024. The company noted the following as highlights of the presentation: Why the refreshed Board is excited about Gildan's future; Gildan's newly refreshed Board contains the right mix of fresh perspectives, historical continuity, and investor input; Glenn Chamandy is no longer the CEO that Gildan needs and there was a clear case for change in 2023 after he irreparably broke the trust of Gildan's Board; Vince Tyra the right CEO to scale Gildan in an increasingly complex and fiercely competitive global environment; Gildan has a thoughtful, long-term plan in place and is successfully executing its strategic priorities. Conversely, Browning West and Glenn Chamandy's plan puts shareholders at risk; Browning West has and continues to repeatedly ignore Gildan's good faith efforts to find common ground - and ultimately - a resolution for the benefit of all shareholders.

07:16 EDT Tiziana Life Sciences files ODD for intranasal foralumab - Tiziana Life Sciences announced it has submitted an FDA request to obtain Orphan Drug Designation, ODD, for intranasal foralumab for the treatment of non-active secondary progressive Multiple Sclerosis. This request would make foralumab the first therapy for na-SPMS to receive Orphan Drug Designation. Our request is supported by clinical and non-clinical evidence of Foralumab's effectiveness in na-SPMS. The prevalence estimates, in part, are supported from the Brigham & Women's Hospital, Boston, Massachusetts, longitudinal study, the CLIMB data of which allowed the estimate of na-SPMS in the population.

07:14 EDT BioCryst's ORLADEYO approved in Mexico - BioCryst Pharmaceuticals announced that the Federal Commission for Protection against Health Risks, COFEPRIS, in Mexico has granted approval for oral, once-daily ORLADEYO for the prophylaxis of hereditary angioedema, HAE, attacks in adults and pediatric patients 12 years of age or older. "With this decision by COFEPRIS, ORLADEYO is now approved in four countries in the pan-Latin America region. We are proud to work with our partner, Pint Pharma, to bring our oral, once-daily prophylactic therapy to people living with HAE who are in need of new treatment options in Mexico and throughout LATAM," said Charlie Gayer, chief commercial officer of BioCryst. BioCryst has an exclusive collaboration with Pint Pharma GmbH to register and promote ORLADEYO in the pan-Latin America region. Under the terms of the agreement, Pint is responsible for obtaining and maintaining all marketing authorizations and for commercializing ORLADEYO in LATAM. ORLADEYO has previously been approved in this region by regulatory agencies in Chile, Argentina and Brazil.

07:12 EDT NJ TRANSIT awards New Flyer contract for up to 1,300 Xcelsior buses - NFI Group announced that NFI subsidiary New Flyer of America has been awarded a contract from the New Jersey Transit Corporation for the purchase of up to 1,300 Xcelsior 40-foot clean-diesel transit buses. This contract is pursuant to the November 2023 NJ TRANSIT Board authorization for NJ TRANSIT to enter into contracts for 550 40-foot transit buses and options to purchase up to 750 additional 40-foot transit buses. New Flyer has received an initial firm order for 175 buses from NJ TRANSIT with the option to purchase up to 1,125 additional 40-foot buses. New Flyer added this award, both firm orders and options, to its backlog in the first quarter of 2024.

07:10 EDT Bitfarms announces termination of CEO Morphy, Bonta named interim CEO - Bitfarms announces that Geoffrey Morphy, who had been continuing as President and Chief Executive Officer pending an executive search for a replacement as announced on March 25, 2024, has been terminated effective immediately. Morphy also no longer serves as a director of the Company. On May 10, 2024, Morphy filed a Statement of Claim in the Superior Court of Ontario against the Company claiming damages for breach of contract, wrongful dismissal and aggravated and punitive damages in the amount of USD$27 million. The Company believes the claims are without merit and intends to defend itself vigorously. Nicolas Bonta, Chairman and Co-Founder of the Company, has been appointed interim President and Chief Executive Officer, and will lead the Company until the executive search is completed and his successor is appointed. The Company also announced that the CEO executive search is nearing completion and that the Company will be appointing a new CEO in the next several weeks.

07:08 EDT Fulcrum Therapeutics sees cash runway into 2027 - Based on its current operating plans, Fulcrum now expects that its cash, cash equivalents, and marketable securities as of March 31, 2024, together with the $80.0 million upfront payment to be received from Sanofi under the collaboration and license agreement, will be sufficient to fund its operating requirements into 2027.

07:06 EDT Apogee expects cash to fund operations into Q1 of 2028 - Cash Position: As of March 31, 2024, Apogee had cash, cash equivalents and marketable securities of $816.2 million. Apogee expects that its existing total cash will enable it to fund its current operating expenses into the first quarter of 2028

07:05 EDT KKR acquires Class A logistics property in Nashville Airport submarket, no term - KKR announced that KKR has acquired a two-building Class A logistics property in the Nashville Airport submarket. Terms of the transaction were not disclosed. The two-building logistics property is strategically located adjacent to Nashville International Airport, with direct access to downtown Nashville and immediate proximity to the I-24, I-40, and I-65 major interstate trucking highways. The second of the two multi-tenant industrial buildings was completed in 2023. The property features 30-foot and 32-foot clear heights with cross-dock and rear-loading, excess power, and excellent access and site circulation. "2 Dell Parkway is an exceptional property that aligns with our long-time strategy of investing in strategically-located, modern logistics assets with flexible spaces that deliver great value to a wide range of quality tenants," said Ben Brudney, a Managing Director in the Real Estate group at KKR who oversees the firm's industrial investments in the United States. "Nashville is continuing to experience outsized growth driven by favorable long-term demographic trends and has been a successful market for our industrial strategy. We are pleased to add this high-quality asset to our portfolio, particularly given its airport adjacent location."

07:03 EDT Squarespace to go private in $6.9B all-cash transaction with Permira - Squarespace announced that it has entered into a definitive agreement to go private by Permira, the global private equity firm, in an all-cash transaction valued at approximately $6.9B. Under the terms of the agreement, Squarespace stockholders will receive $44.00 per share in cash representing a transaction valued at over $6.6B on an equity value basis and approximately $6.9B on an enterprise value basis. The purchase price represents a premium of approximately 29% over Squarespace's 90-day volume weighted average trading price, and a premium of 15% over Squarespace's closing share price of $38.19 on the NYSE on May 10. Upon completion of the transaction, Squarespace will become a privately held company with the flexibility and resources to invest in enabling entrepreneurs to build better online brands and more easily transact with their customers. Anthony Casalena will roll over a substantial majority of his existing equity and continue to be one of the largest shareholders following this transaction. He will continue to serve as Squarespace's Chief Executive Officer and Board Chairman, and lead the business in all aspects of its operations, along with Squarespace's current leadership team, who are expected to continue their roles following the close of the transaction. Due to the pending transaction, the company will no longer hold its previously announced Investor Day scheduled for May 15. The transaction was unanimously approved and recommended by a Special Committee of the Squarespace Board of Directors, composed entirely of independent and disinterested directors, and unanimously approved by the Board of Directors. The transaction is subject to receipt of regulatory approvals. Upon satisfaction of these and other customary closing conditions, the transaction is expected to close by the fourth quarter of 2024. Upon completion of the transaction, Squarespace's common stock will no longer be publicly listed, and Squarespace will become a privately-held company.

06:56 EDT Aecom selected by TxDOT to deliver drainage tunnels in Austin, TX - Aecom has been selected by the Texas Department of Transportation, or TxDOT, to provide project inspection services for the construction of drainage tunnels for the next phase of its $4.5B Capital Express Central project in Austin. The project includes the delivery of two large-diameter drainage tunnels and a pump station to provide storm drainage infrastructure relieve flooding and improve safety along the I-35 corridor serving the state's capital.

06:37 EDT Fisker adds three new dealer partner locations in the U.S. - Fisker announced that the company has added three new dealer partner locations in the U.S., in California and New Jersey. Fisker also waived the $2,438 Destination and Handling fee on model year 2023 Fisker Ocean Extremes and Ultras in the US, and announced that the model year 2023 Sport trim level has sold out in the continental U.S.

06:31 EDT Mitek Systems names Scott Carter as Interim CEO, effective June 1 - Mitek Systems announced that the company's Board of Directors has appointed Scott Carter as Interim CEO, effective June 1. The company will terminate the employment of Mitek's current CEO, Max Carnecchia, on May 31. At the request of the Board, Carnecchia will remain a member of the Board of Directors and be available to assist with the CEO transition process. The Board has engaged the services of a leading global executive search firm and has commenced the search for a new CEO.

06:06 EDT AC Immune, Takeda sign worldwide option and license agreement - Takeda (TAK) and AC Immune (ACIU) announced an exclusive, worldwide option and license agreement for AC Immune's active immunotherapies targeting toxic forms of amyloid beta, including ACI-24.060 for the treatment of Alzheimer's disease. AC Immune will be responsible for completing the ABATE trial. Following option exercise, Takeda would conduct and fund all further clinical development and be responsible for all global regulatory activities as well as worldwide commercialization. Under the terms of the agreement, AC Immune will receive an upfront payment of $100M and be eligible to receive an option exercise fee and additional potential development, commercial and sales-based milestones of up to approximately $2.1B if all related milestones are achieved over the course of the agreement. Upon commercialization, AC Immune will be entitled to receive tiered double-digit royalties on worldwide net sales.

06:03 EDT Fulcrum Therapeutics, Sanofi enter collaboration and license agreement - Fulcrum Therapeutics (FULC) announced that it has entered into a collaboration and license agreement with Sanofi (SNY) for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy. Under the collaboration and license agreement, Sanofi obtains exclusive commercialization rights for losmapimod outside of the U.S. Fulcrum will receive an upfront payment of $80M, and is eligible to receive $975M in potential milestones, plus royalties on ex-U.S. product sales; parties will share future global development costs 50:50. In addition, Fulcrum and Sanofi will equally share future global development costs.

05:28 EDT Regeneron, Sanofi announce FDA acceptance for priority review of Dupixent sBLA - Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for Priority Review the supplemental Biologics License Application, or sBLA, for Dupixent as an add-on maintenance treatment for adolescents aged 12 to 17 years with inadequately controlled chronic rhinosinusitis with nasal polyposis, or CRSwNP. The target action date for the FDA decision is September 15. Dupixent is currently approved as an add-on maintenance treatment for adults with CRSwNP whose disease is not adequately controlled.

05:17 EDT Imperial Oil announces updated agreement with E3 Lithium - E3 Lithium announced an update to its agreement with Imperial Oil. As part of E3 Lithium and Imperial's continued collaboration under the agreement first announced in June 2022, the two companies have agreed to increase access to additional freehold lands across the Clearwater Area. The company has also agreed to extend the term of the warrants for an additional 12 months, now exercisable until July 8, 2025. E3 Lithium proposes to extend the expiry date of 3,413,979 outstanding prepaid common share purchase warrants of the company issued to Imperial Oil Limited for which the company had received a prepayment of $6.35M on July 8, 2022. Each Warrant provides IOL the non-transferable and non-refundable option to exercise the Warrant for one common share of the Company at a price of $1.86 for a period of 24 months from the date of grant at no further cost to IOL. No Warrants have been exercised to date and none are held by insiders of the company. Subject to the approval of the TSX Venture Exchange, the expiration of the warrants will be extended from July 8, 2024 to July 8, 2025. All other terms of the Warrants would remain unchanged and in full force and effect. No action will be required on the part of the holder of the Warrants to give effect to the aforementioned amendment.

05:10 EDT Zapata AI CFO Mimi Flanagan to depart, Sumit Kapur to succeed - Zapata announced that Sumit Kapur will join the organization as CFO, effective May 20 and as Zapata AI's VP, finance during a short transition period, effective immediately. He spent nearly 12 years serving as CFO at 3Degrees. He will succeed Mimi Flanagan, who is leaving the company for personal reasons.